Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACR-368 + Low Dose Gemcitabine in R/M HNSCC
NCT06597565Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of prexasertib in head and neck squamous cell carcinoma (HNSCC), sponsored by Moffitt Cancer Center. Started Sep 2024; status: recruiting.
02
Drugs
prexasertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06597565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597565.